Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis

Singal, Amit G.; Pillai, Anjana; Tiro, Jasmin A.

doi:10.1371/journal.pmed.1001624

Cited by 661 publications

(579 citation statements)

References 71 publications

Supporting

Mentioning

518

Contrasting

Unclassified

Order By: Relevance

“…As of yet, no study has examined the time between diagnosis and treatment [13]. Our study indicates that patients with HCV related HCC have a longer wait time from diagnosis to treatment compared to patients with HBV.…”

Section: Reasons That Distinguish Hbv From Hcv Related Hcc In Time Frmentioning

confidence: 77%

Disparities in Time to Treatment of Hepatocellular Carcinoma in Patients with Hepatitis B Virus versus Hepatitis C Virus

Wu¹,

Hochman²,

Goldberg³

et al. 2017

Can Res

View full text Add to dashboard Cite

Section: Reasons That Distinguish Hbv From Hcv Related Hcc In Time Frmentioning

confidence: 77%

Disparities in Time to Treatment of Hepatocellular Carcinoma in Patients with Hepatitis B Virus versus Hepatitis C Virus

Wu¹,

Hochman²,

Goldberg³

et al. 2017

Can Res

View full text Add to dashboard Cite

“…A terápia stádiumfüggő, a kuratív eljárásoktól (reszekció, transzplantáció, percutan ablatio) a transarterialis chemo-és radioembolisatión át a multikináz inhibitor sorafenib alkalmazásáig. Mindennek a NASH-eredetű HCC egyre nagyobb globális prevalenciája ad hangsúlyt [63,64].…”

Section: A Nash-cirrhosis éS a Hcc Terápiájaunclassified

Nem alkoholos zsírmáj és hepatocellularis carcinoma – 2016

Pár

2016

Orvosi Hetilap

View full text Add to dashboard Cite

Az utolsó évtizedben a fejlett országokban a nem alkoholos zsírmáj lett a leggyakrabban diagnosztizált krónikus májbetegség. Ugyanakkor e kórképnek, de különösen súlyosabb formájának, a nem alkoholos steatohepatitisnek a szerepe bizonyított a hepatocellularis carcinoma gyakoriságának drámai megnövekedésében. A fő kockázati tényezők a genetikai prediszpozíció mellett az obesitas és a diabetes, valamint a kórfolyamatban gyakran fibrosishoz vezető alacsony fokú krónikus gyulladás. A patogenezisben a szabad zsírsavak és citokinek, a lipotoxicitás, az inzulinrezisztencia, a mikro-RNS-diszreguláció és a bél-baktériumflóra megváltozása kulcsfontosságú. A nem alkoholos zsírmáj kezelése -obesitasban a testsúlycsökkentés és fizikai aktivitás, diabetesben a metformin, dyslipidaemiában a statinok és új lehetőségként az obetikólsav -e betegség következményeként kialakuló hepatocellularis carcinoma prevenció-ját is szolgálhatja. Orv. Hetil., 2016, 157(25), 987-994.Kulcsszavak: nem alkoholos zsírmáj, nem alkoholos steatohepatitis, hepatocellularis carcinoma, genetika, citokinek, inzulinrezisztencia, mikro-RNS, bél-baktériumflóra, diagnózis, szűrés, terápia, obetikólsav, daganatprevenció Non-alcoholic fatty liver disease and hepatocellular carcinoma -2016In the past decade non-alcoholic liver disease became the most frequently diagnosed liver disease in developed countries. At the same time, the dramatic rise in the incidence of hepatocellular carcinoma is attributed to this common metabolic disorder, and mainly to its severe form, non-alcoholic steatohepatitis. The risk factors of these associated diseases are genetic predisposition, obesity and diabetes as well as chronic low grade necro-infammation, which often leads to liver fibrosis. Free fatty acids, cytokines, lipotoxicity, insulin resistance, microRNS dysregulation and alteration in intestinal microbiota play a pivotal role in the pathogenesis. Treatment of non-alcoholic fatty liver disease -weight reduction and physical exercise in obesity, metformin in diabetes, statins in dyslipidemia and, as a new option, obeticholic acid -may diminish the risk of the hepatocellular carcinoma related to this metabolic disease.Keywords: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hepatocellular carcinoma, genetics, cytokines, insulin resistance, microRNA, intestinal microbiota, diagnosis, surveillance, treatment, obeticholic acid, cancer prevention Rövidítések ALP (GPT) = alanin-aminotranszferáz; AMPK = adenozinmonofoszfát-aktivált proteinkináz; BMI = testtömegindex; CDA = chenodezoxikólsav; DNS = dezoxiribonukleinsav; FFA = szabad zsírsav; FGF = fibroblastnövekedési faktor; HBV = hepatitis B-vírus; HCC = hepatocellularis carcinoma; HCV = hepatitis C-vírus; HR = hazard ratio; HSC = hepaticus csillag-(stellatum) sejt; IL = interleukin; IR = inzulinrezisztencia; IRS-1 = inzulinreceptor-szubsztrát-1; KS = Kupffer-sejt; LSP = lipopoliszacharida; MAPK = mitogénaktivált proteinkináz; miR = mikro-RNS; MMP = metalloproteináz; NAFLD = nem alkoholos zsírmáj; NASH = nem al...

show abstract

“…[22][23][24][25][26][27] All studies have demonstrated that patients who achieve an SVR have better outcomes with respect to cirrhosis, development of HCC, and all-cause mortality. A report by Cozen et al compared outcomes for treated and nontreated patients in two representative diverse populations.…”

Section: Introductionmentioning

confidence: 99%

Effect of Treatment for CHC on Liver Disease Progression and Hepatocellular Carcinoma Development in African Americans

Reddy¹,

Naylor²,

Hakim³

et al. 2015

JCTH

View full text Add to dashboard Cite

Background and Aims: African Americans (AA) historically have a low response rate to hepatitis C therapies, and there is limited information available for this patient population regarding the development and treatment of chronic hepatitis C (CHC). The aim of this study was to evaluate liver disease progression and hepatocellular carcinoma (HCC) development in AA with CHC. Methods: Between 1995 and 2008, 246 AA patients with CHC were identified from a database of patients and followed until 2012-2013 (average 8 years) or the development of HCC after 2008. Results: Viral clearance (intent to treat; sustained virus response (SVR)) was achieved in 15% of patients with interferon based therapies with or without ribavirin. AA patients who achieved an SVR (n=22) did not develop HCC or new onset cirrhosis, whereas the HCC incidence in untreated AA patients was 23% (51/203). Patients who achieved an SVR also had improved fibrosis, as defined by the AST Platelet Ratio Index (APRI) and Fibrosis-4 (FIB-4) score, relative to nonresponders and untreated patients. Conclusions: The severity of liver disease at the first visit (except for cirrhosis) correlated with the development of HCC, but because of the overlap in values between patients, these measurements were not useful for predicting individual risk. Since cirrhosis at the first visit was not a predictive factor, treatment with newer antiviral therapies is the best option for reducing the incidence of advanced liver disease and its harmful outcomes in the AA population.

show abstract

Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis

Abstract: Amit Singal and colleagues conducted a systematic review of the evidence that surveillance for hepatocellular carcinoma in patients with cirrhosis improves early detection, receipt of curative treatment, and overall survival. Please see later in the article for the Editors' Summary

Cited by 661 publications

References 71 publications

Disparities in Time to Treatment of Hepatocellular Carcinoma in Patients with Hepatitis B Virus versus Hepatitis C Virus

Disparities in Time to Treatment of Hepatocellular Carcinoma in Patients with Hepatitis B Virus versus Hepatitis C Virus

Nem alkoholos zsírmáj és hepatocellularis carcinoma – 2016

Effect of Treatment for CHC on Liver Disease Progression and Hepatocellular Carcinoma Development in African Americans

Contact Info

Product

Resources

About